On December 29, the official website of the State Drug Administration showed that Hefei Tianhui Biotech's recombinant human insulin enteric capsules ranked on the same day's drug notification delivery information list. This means that the drug was unsuccessfully approved. In response, on December 30, Tianhui Biotech told Interface News that the termination of the registration application was the company's voluntary withdrawal and part of the company's overall strategy. In fact, the biggest highlight of ORMD-0801 is that it is an oral insulin, which is more convenient than current insulin injections. Currently, no oral insulin has been approved worldwide, and Novo Nordisk has terminated similar programs.

On December 29, the official website of the State Drug Administration showed that Hefei Tianhui Biotech's recombinant human insulin enteric capsules ranked on the same day's drug notification delivery information list. This means that the drug was unsuccessfully approved. In response, on December 30, Tianhui Biotech told Interface News that the termination of the registration application was the company's voluntary withdrawal and part of the company's overall strategy. In fact, the biggest highlight of ORMD-0801 is that it is an oral insulin, which is more convenient than current insulin injections. Currently, no oral insulin has been approved worldwide, and Novo Nordisk has terminated similar programs.